

13th September, 2024

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: BSE - 524500

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051
Scrip Code: NSE - KILITCH

Sub: Submission of acknowledgement received from Securities and Exchange Board of India for the report submitted under regulation 10(7) of SEBI(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir,

Please find enclosed herewith the acknowledgement received from Securities and Exchange Board of India for the report submitted under regulation 10(7) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for your record.

We request you to kindly take note of the same and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For Kilitch Drugs (India) Limited

Mukund Mehta Managing Director









Not Verified

1 2 SEP 2024


मृत्र /MUMBAI

#### Mira Bhavin Mehta

11th November, 2024

To, The Securities and Exchange Board of India Plot No.C4-A, 'G' Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400051

Dear Sir,



With reference to the above captioned subject, please find enclosed herewith the Report to be submitted pursuant to Regulation 10(7) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011, in respect of inter-se transfer executed under Regulation 10(1)(a)(i) and (ii) of SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011, as amended, along with fees of Rs.1,50,000/-.

Request you kindly take the same on record and acknowledge the receipt.

Thanking You,

Yours' Faithfully,


Mira Bhavin Mehta

#### Encl:-

- 1. Disclosures under Regulation 10(7)
- 2. Annexure A
- 3. Annexure B
- 4. Annexure C
- 5. Annexure D
- 6. DD of Rs.1,50,000/-

# Report to SEBI in respect of any acquisition made in reliance upon exemption provided for in regulation 10(1)(a)(i) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011

1	General Details					
	a.	Name, address, telephone no., e-mail of acquirer(s) {In case there are multiple acquirers, provide full contact details of any	Mira Bhavin Mehta  Address: A-1903, Beaumonte Tower A, Plot			
		one acquirer (the correspondent acquirer) with whom SEBI shall correspond.}	C56 PT, Kamani Marg, Near Sion Circle, Sion, Mumbai - 400022			
			Tel. No.:- 9819724960			
			E-mail:- miramehta@kilitch.com			
	b.	Whether sender is the acquirer (Y/N)	Yes			
	c.	If not, whether the sender is duly authorized				
	•	by the acquirer to act on his behalf in this	NA			
		regard (enclose copy of such authorization)				
	d.	Name, address, Tel no. and e-mail of	NA			
		sender, if sender is not the acquirer				
2	Con	Compliance of Regulation 10(7)				
	a.	Date of Report	11 <sup>th</sup> September, 2024			
	b.	Whether report has been submitted to SEBI within 21 working days from the date of the acquisition	Yes			
	c.	Whether the report is accompanied with fees as required under Regulation 10(7)	Yes			
3	Cor	npliance of Regulation 10(5)				
Ť	a.	Whether the report has been filed with the	Yes			
		Stock Exchanges where the shares of the				
		Company are listed, atleast 4 working days				
		before the date of the proposed acquisition.				
	Ъ.	Date of Report	13 <sup>th</sup> August, 2024			
4	Cor	mpliance of Regulation 10(6)				
	a.	Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed within 4 working days	Yes			
		of the acquisition				
	b.	Date of Report	29 <sup>th</sup> August, 2024			
5		Details of the Target Company				
	a.	Name & address of TC	Kilitch Drugs (India) Limited			
	b.	Name of the Stock Exchange(s) where the shares of the TC are listed	National Stock Exchange of India Limited & BSE Limited			
6	Det	Details of the acquisition				
	a.	Date of acquisition	23 <sup>rd</sup> August, 2024			
	b.	Acquisition price per share (in Rs.)	NIL [Inter Se Transfer by Gift]			



	d	If shares of the TC are frequently traded, volume-weighted average market price (VWAP) of such shares for a period of sixty trading days preceding the date of issuance	NSE: Rs. 351 BSE: Rs. 351			
	С	Confirm whether the acquirer(s) and the seller(s) are 'immediate relatives' as defined in the Regulation 2(1).	As per Annex	ture – 'A'		
	ь	Specify the relationship between the acquirer/s and the seller/s.	Immediate Re	elative (Hu	usband)	
	a	Provide the names of the seller/s	Bhavin Muku	ınd Mehta		
/.		ulation 10(1)(a)(i)	which the	mstant a	equisition D	ciongs -
7.	Info	Total rmation specific to the exemption category	33,64,184	20.92	25,23,138	15.69
		Bhavin Mukund Mehta	33,64,184	20.92	25,23,138	15.69
	e.		No. of Shares	total share capital /voting rights of TC	No: of Shares	total share capital /voting rights of TC
	Shareholding of seller/s in TC (in terms of no: & as a percentage of the total share/voting capital of the TC)		Before the acquisition % w.r.t		After the acquisition	
		Total	1,11,34,173	69.23	1,11,34,173	69.23
		iv. Kilitch Company (Pharma) Limited	6629342	41.22	66,29,342	41.22
		iii. Bhavin Mukund Mehta	3364184	20.92	25,23,138	15.69
		ii. Mukund Mehta	1140647	7.09	11,40,647	7.09
	d.	<ul> <li>Acquirer(s) and PACs (other than sellers)(*)</li> <li>i. Mira Bhavin Mehta</li> </ul>	0	0	8,41,046	5.23
	a		No: of Shares	% w.r.t total share capital /voting rights of TC	No: of Shares	% w.r.t total share capital /voting rights of TC
		Shareholding of acquirer/s and PACs individually in TC ( in terms of no. & as a percentage of the total share/voting capital of the TC)(*)	Before the acquisition		After the acquisition	
	c.	Regulation which would have been triggered off, had the report not been filed under Regulation 10(7) (whether Regulation 3(1), 3(2), 4 or 5)		Regulation	on 3(1)	



	of notice regarding the proposed acquisition to the stock exchanges where the TC is listed.	
e	If shares of the TC are infrequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	NA
f	Confirm whether the acquisition price per share is not higher by more than twenty-five percent of the price as calculated in (d) or (e) above as applicable.	As per Annexure – 'B'
g	Date of issuance of notice regarding the proposed acquisition to the stock exchanges where the TC is listed	13 <sup>th</sup> August, 2024
h	Whether the acquirers as well as sellers have complied with the provisions of Chapter V of the Takeover Regulations (corresponding provisions of the repealed Takeover Regulations 1997) (Y/N). If yes, specify applicable regulation/s as well as date on which the requisite disclosures were made along with the copies of the same.	YES As per Annexure – 'C'
i	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a)(i)with respect to exemptions has been duly complied with.	As per Annexure – 'D'

I hereby declare that the information provided in the instant report is true and nothing has been concealed there from.

Mira Bhavin Mehta Place: Mumbai

#### Mira Bhavin Mehta

A-1903, Beaumonte Tower A, Plot C56 PT, Kamani Marg, Near Sion Circle, Sion, Mumbai - 40002

## ANNEXURE A TO POINT NO. 7(c) OF FORM UNDER REGULATION 10(7) [RE: KILITCH DRUGS (INDIA) LIMITED]

#### **DECLARATION**

I, Mira Bhavin Mehta, do and hereby confirm and declare that the acquirer and the seller/s are 'immediate relatives' as defined in the Regulation 2(l) as mentioned in Point No. 7 (c) of form specified under Regulation 10(7).

Bhavin Mehta Place: Mumbai

# ANNEXURE B TO POINT NO. 7(f) OF FORM UNDER REGULATION 10(7) [RE: KILITCH DRUGS (INDIA) LIMITED]

#### **DECLARATION**

I, Mira Bhavin Mehta, do and hereby confirm and declare that, the acquisition price per share is not higher by more than twenty-five percent of the price calculated as per volume-weighted average market price (VWAP) of such shares for a period of sixty trading days preceding the date of issuance of notice regarding the proposed acquisition to the stock exchanges where the Kilitch Drugs (India) Limited (i.e. Target Company) is listed.

Mira Bhavin Mehta

Place: Mumbai

## ANNEXURE C TO POINT NO. 7(h) OF FORM UNDER REGULATION 10(7) [RE: KILITCH DRUGS (INDIA) LIMITED]

#### **DECLARATION**

Based on the information received and documents furnished by Kilitch Drugs (India) Limited (i.e. Target Company) I, Mira Bhavin Mehta, do and hereby confirm and declare that, the acquirers as well as sellers have complied with the provisions of Chapter V of the SEBI Takeover Regulations.

The details of the compliances made under Chapter V of the Takeover Regulations by the Acquirers and Sellers are as under:-

Sr. No.	Compliance	Name of the Acquirer / Seller	Date
1	Under Regulation 29 (2) of SEBI(Substantial Acquisition of Shares and Takeover) Regulations, 2011	Mira Bhavin Mehta [Acquirer]	27 <sup>th</sup> August, 2024
2	Under Regulation 29 (2) of SEBI(Substantial Acquisition of Shares and Takeover) Regulations, 2011	Bhavin Mukund Mehta [Seller]	27 <sup>th</sup> August, 2024

Mira Bhavin Mehta

Place: Mumbai

# ANNEXURE D TO POINT NO.7(i) OF FORM UNDER REGULATION 10(7) [RE: KILITCH DRUGS (INDIA) LIMITED]

#### **DECLARATION**

I, Bhavin Mehta, do and hereby confirm and declare that, all the conditions specified under regulation 10(1)(a)(i) with respect to exemptions has been duly complied with.

Mira Bhavin Mehta

Place: Mumbai

MC\_1

HDFC BANK

A/C PAYEE ONLY NOT NEGOTIABLE

### MANAGER'S CHEQUE VALID FOR 3 MONTHS ONLY

1 1 0 9 2 0 2 4

हुँ Pay SECURITIES AND EXCHANGE BOARD OF INDIA इंड अदा करे	маюргомного сымаюргомного сыма
	या उनके आदेश पर
Rupees रुपये ONE LAKH FIFTY THOUSAND ONLY.	*1,50,000.00
MIRA BHAVIN MEHTA  SION EAST - SION CIRCLE  MUMBAI - 400022  REF. No. 001632509680	FOR VALUE RECEIVED

"OB9164" 400240030: 999989" 12